- Trial Phase
- Phase 2 (complete); preparing Phase 3
- Time to Market
- At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
- Why 4/10
- Nebokitug is a mid-stage asset (Phase 2 complete, Phase 3 not yet initiated) with no dated binary catalyst (PDUFA, pivotal readout) scheduled within the next ~12 months. The merger with Scipher Medicine (expected close Q4 2026) is a corporate event, not a drug catalyst. The stock already surged ~80% into the merger announcement. ImpactScore is capped at 5 per rubric (no hard dated binary) and set at 4 as the next drug-specific catalyst (Phase 3 start/data) is likely >12 months away.
The just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal — much of the near-term re-rating may be priced in.
Price Chart
Executive Summary
Nebokitug is Chemomab's only clinical-stage asset — a first-in-class antibody targeting CCL24 for fibro-inflammatory diseases. Phase 2 data in PSC (a rare liver disease with NO approved therapies) was positive and published in a top journal. The FDA has aligned on a streamlined single-trial Phase 3 path. However, the Phase 3 has not launched due to funding constraints. On July 8, 2026, Chemomab announced a merger with Scipher Medicine (all-stock; Chemomab holders get ~32% of the combined entity plus CVRs), bringing $30M in financing and a new AI-guided Phase 2 RA program. The stock had already surged ~80% into the deal. The drug's value proposition is strong — a large unmet-need market with regulatory tailwinds — but execution risk on Phase 3 financing, dilution from the merger, and the very early-stage RA program keep the read mixed near-term.
How It Works
Nebokitug is a lab-made antibody (a type of protein) that blocks a specific signaling molecule called CCL24. CCL24 acts like a "recruiter" that calls in inflammatory cells and activates scar-forming cells in organs. By neutralizing CCL24, nebokitug aims to interrupt both inflammation and fibrosis (scarring) in diseases where this process goes haywire — such as the bile ducts in PSC, the skin/lungs in systemic sclerosis, and potentially joints in rheumatoid arthritis.
Trial Status
Nebokitug completed the Phase 2 SPRING trial (n=76, double-blind, placebo-controlled, 15 weeks + 48-week open-label extension) in primary sclerosing cholangitis (PSC), showing dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic biomarker improvements. Results were published in the American Journal of Gastroenterology (Nov 2025). A Phase 3 design is aligned with FDA (single pivotal trial, clinical event endpoint, no liver biopsy), but trial initiation has been contingent on financing. The SSc program has an open IND. Post-merger, an AI-guided Phase 2 RA trial is planned.
The Two-Sided Case
Upcoming Catalysts
- Merger with Scipher Medicine — expected close in Q4 2026 (shareholder vote, Nasdaq listing change to new ticker)
- Phase 3 PSC trial initiation — contingent on post-merger financing; no firm date announced
- AI-guided Phase 2 RA trial planning — expected to be unveiled post-merger
- Potential partnering/licensing deals for nebokitug (the company noted partnering options were advancing prior to merger)
- Scientific conference presentations of ongoing data analyses from SPRING trial
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Chemomab Therapeutics Ltd. 6-K CMMB ·Originating report